Fulgent Genetics, Inc. (FLGT)

NASDAQ: FLGT · IEX Real-Time Price · USD
21.35
-0.07 (-0.33%)
May 22, 2024, 4:00 PM EDT - Market closed
-0.33%
Market Cap 638.88M
Revenue (ttm) 287.53M
Net Income (ttm) -165.95M
Shares Out 29.92M
EPS (ttm) -5.57
PE Ratio n/a
Forward PE 7.94
Dividend n/a
Ex-Dividend Date n/a
Volume 114,948
Open 21.36
Previous Close 21.42
Day's Range 21.17 - 21.57
52-Week Range 19.88 - 44.09
Beta 1.43
Analysts Hold
Price Target 30.00 (+40.52%)
Earnings Date May 3, 2024

About FLGT

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to h... [Read more]

Sector Healthcare
IPO Date Sep 29, 2016
Employees 1,184
Stock Exchange NASDAQ
Ticker Symbol FLGT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $30.0, which is an increase of 40.52% from the latest price.

Price Target
$30.0
(40.52% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and ...

8 days ago - Business Wire

Fulgent Reports First Quarter 2024 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

19 days ago - Business Wire

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

5 weeks ago - Business Wire

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

3 months ago - Business Wire

Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

3 months ago - Business Wire

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Testing offers CBR families the opportunity to proactively seek additional information about their child's health ‍TRUMBULL, Conn. and EL MONTE, Calif.

Other symbols: COO
3 months ago - PRNewsWire

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

6 months ago - Business Wire

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

7 months ago - Business Wire

Fulgent Reports Third Quarter 2023 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

7 months ago - Business Wire

Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

7 months ago - Business Wire

Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

7 months ago - Business Wire

Fulgent Reports Second Quarter 2023 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

10 months ago - Business Wire

Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

11 months ago - Business Wire

Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

1 year ago - Business Wire

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

1 year ago - Business Wire

Fulgent Reports First Quarter 2023 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...

1 year ago - Business Wire

Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeu...

1 year ago - Business Wire

Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research

Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics for biomarker discovery, clinical research, and single-cell MRD developme...

1 year ago - PRNewsWire

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therape...

1 year ago - Business Wire

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeu...

1 year ago - Business Wire

Fulgent to Participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic devel...

1 year ago - Business Wire

Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient ca...

1 year ago - Business Wire

NOTICE For Investors In NASDAQ: FLGT: Lawsuit Against Fulgent Genetics, Inc. Announced by Shareholders Foundation

San Diego, California--(Newsfile Corp. - January 24, 2023) -  The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Fulgent Genetics, Inc. (NASDAQ: FLGT) share...

1 year ago - Newsfile Corp

INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.'s Directors and Officers for Breach of Fiduciary Duties – FLGT

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of cert...

1 year ago - Business Wire

Fulgent Expands Board of Directors with Addition of Reggie Groves

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, ...

1 year ago - Business Wire